The GlaxoSmithKline PLC (GSK) Forecasted to Post Q3 2016 Earnings of $0.72 Per Share

The GlaxoSmithKline PLC (GSK) Forecasted to Post Q3 2016 Earnings of $0.72 Per Share

GlaxoSmithKline PLC (NYSE:GSK) – Equities researchers at Jefferies Group issued their Q3 2016 EPS estimates for shares of GlaxoSmithKline PLC in a research report issued on Thursday. Jefferies Group analyst J. Holford anticipates that the brokerage will post earnings per share of $0.72 for the quarter. Jefferies Group currently has a “Buy” rating on the stock.

Several other equities analysts also recently issued reports on the company. Zacks Investment Research downgraded GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Friday, September 23rd. Piper Jaffray Cos. began coverage on GlaxoSmithKline PLC in a research report on Friday, September 23rd. They issued an “overweight” rating for the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 22nd. Finally, Bank of America Corp. restated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Tuesday, September 20th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and an average target price of $47.86.

GlaxoSmithKline PLC (NYSE:GSK) opened at 41.68 on Friday. The company has a 50 day moving average price of $43.15 and a 200-day moving average price of $42.93. The firm has a market cap of $101.30 billion, a price-to-earnings ratio of 2605.00 and a beta of 0.89. GlaxoSmithKline PLC has a 52-week low of $37.82 and a 52-week high of $45.58.

The company also recently disclosed a dividend, which was paid on Thursday, October 13th. Stockholders of record on Friday, August 12th were given a dividend of $0.494 per share. The ex-dividend date of this dividend was Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is currently 6,166.67%.

Several hedge funds and other institutional investors have recently bought and sold shares of GSK. Simmons Bank purchased a new position in GlaxoSmithKline PLC during the first quarter valued at $1,641,000. Loomis Sayles & Co. L P boosted its position in GlaxoSmithKline PLC by 60.6% in the first quarter. Loomis Sayles & Co. L P now owns 20,631 shares of the pharmaceutical company’s stock valued at $837,000 after buying an additional 7,788 shares in the last quarter. Forester Capital Management LTD boosted its position in GlaxoSmithKline PLC by 69.6% in the first quarter. Forester Capital Management LTD now owns 4,630 shares of the pharmaceutical company’s stock valued at $214,000 after buying an additional 1,900 shares in the last quarter. Chubb Ltd. purchased a new position in GlaxoSmithKline PLC during the first quarter valued at $16,220,000. Finally, Glovista Investments LLC purchased a new position in GlaxoSmithKline PLC during the first quarter valued at $5,527,000. 8.79% of the stock is owned by institutional investors.

GlaxoSmithKline PLC Company Profile

Related posts

Leave a Comment